In this paper we review some of the preclinical findings which have led us to believe that immunotherapy with interleukin 2 (IL2)/lymphokine activated killer (LAK) cells may be a feasible approach in the management of acute myeloid leukemia. The main clinical and biological results so far obtained with IL2 treatment, and the currently ongoing protocols and strategies are discussed.
Interleukin 2 (IL2) in the management of acute myeloid leukemia: clinical and biological findings / Foa, Roberto; Meloni, Giovanna; Guarini, Anna; Vignetti, Marco; D., Marchis; S., Tosti; A., Gilio Tos; F., Vischia; Mandelli, Franco; F., Gavosto. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - 6:(1992), pp. 115S-116S. (Intervento presentato al convegno 15TH SYMP OF THE INTERNATIONAL ASSOC FOR COMPARATIVE RESEARCH ON LEUKEMIA AND RELATED DISEASES tenutosi a PADUA, ITALY nel OCT 06-11, 1991).
Interleukin 2 (IL2) in the management of acute myeloid leukemia: clinical and biological findings
FOA, Roberto;MELONI, Giovanna;GUARINI, Anna;VIGNETTI, Marco;MANDELLI, Franco;
1992
Abstract
In this paper we review some of the preclinical findings which have led us to believe that immunotherapy with interleukin 2 (IL2)/lymphokine activated killer (LAK) cells may be a feasible approach in the management of acute myeloid leukemia. The main clinical and biological results so far obtained with IL2 treatment, and the currently ongoing protocols and strategies are discussed.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
